Collectively, these data support a self-perpetuating chronometabolic cycle in which circadian disruption both drives and is amplified by MASLD, positioning circadian integrity as a mechanistically central and potentially modifiable axis in disease progression
First of all, according to a validated semiquantitative score, NAFLD was classified as absent (0), mild (1), moderate (2), or severe (3) based on standardized US characteristics of liver echogenicity [35]
Tirzepatide is contraindicated in individuals with personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2
GLP-1 reduces hunger by Slowing gastric emptying Increasing satiety signals Blunting appetite drive This is why people eat less not because of discipline. GIP helps improve metabolic efficiency and insulin response
Abstract Tirzepatide is the first dual GIP/GLP-1 receptor co-agonist approved for the treatment of type 2 diabetes in the USA, Europe, and the UAE
